Skip to content
Alpa Laboratories logo

Alpa Laboratories

ALPA NSE
₹52.45 up 0.25 (0.48%)
Market Cap
₹110 Cr
P/E
27.04

Alpa Laboratories (ALPA) share price was ₹52.20 at the 28 Oct 2026 close; market capitalisation ₹110 Cr; P/E (TTM) 26.91; sector Healthcare. The share price fell 41.6% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 25.2% year on year to ₹23.93 Cr and net profit fell 91.7% year on year to ₹0.98 Cr (compared with Jun 2025). Promoters held 57.19% of Alpa Laboratories in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 50/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹52.20 −38.83 −42.66% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹110 Cr
P/E (TTM)
27.04
EBITDA
₹19.00 Cr
Return on Equity
8.06%
Debt to Equity
0.02
Book Value
₹88.53
EPS (TTM)
₹1.94
52W High
₹93.85
52W Low
₹46.10

Price-based figures as of 29 Oct 2026, 10:54 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,765.9035.034,23,699 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,653.5087.622,56,270 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,595.2072.141,74,787 Cr9.510.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,190.10108.211,18,334 Cr22.330.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.6026.291,17,865 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,337.3034.641,11,622 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,363.1032.661,10,119 Cr3.110.96%11.21%14.88%28,589 Cr3,356 Cr
Alpa Laboratories (this company)
₹52.4527.04110 Cr0.590.00%8.06%8.94%120 Cr4 Cr
Median 8 companies₹1,564.5034.841,18,099 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

50 Average
Overall score

Data confidence 100/100

Category scores

Quality Good 56
Returns, margins, earnings quality 22% weight
Valuation Average 53
Cheap vs sector & own history 24% weight
Growth Poor 37
Sales & profit trajectory 9% weight
Financial Health Strong 69
Solvency, leverage, coverage 9% weight
Momentum Poor 21
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Stock is trading at 0.60 times its book value
  • Company's working capital requirements have reduced from 105 days to 70.6 days

Weaknesses

4
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 1.69% over past five years.
  • Company has a low return on equity of 10.7% over last 3 years.
  • Earnings include an other income of Rs.9.58 Cr.

Technical Indicators

Oscillators

Bearish

Bearish
3
Neutral
5
Bullish
1

Overall

Bearish

Bearish
13
Neutral
5
Bullish
1

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-10.46% lower than 3Y

change over 1 year

Net Income Growth
-23.08% lower than 3Y

change over 1 year

Cash Flow Change
-49.29%

change over 1 year

EBITDA Margin Change
-24.26%

change over 1 year Operating margin -16.55% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
25.43
32.39
27.31
23.61
21.44
24.94
26.15
39.92
19.11
26.26
29.05
31.4
23.93
Expenses
26.57
29.04
24.88
20.1
20.91
21.62
25.41
39.72
18.68
28.51
27.54
27.8
27.89
Operating Profit
-1.14
3.35
2.43
3.51
0.53
3.32
0.74
0.2
0.43
-2.25
1.51
3.6
-3.96
OPM %
-4.48%
10.34%
8.9%
14.87%
2.47%
13.31%
2.83%
0.5%
2.25%
-8.57%
5.2%
11.46%
-16.55%
Other Income
4.47
2.95
3.55
3.98
5.16
6.91
8.8
2.48
11.94
3.06
0.91
-0.16
5.77
Interest
0.02
0.02
0.02
0.29
0.05
0.05
0.09
0.02
0.05
0.03
0.03
0.15
0.11
Depreciation
0.28
0.49
0.66
0.52
0.54
0.53
0.55
0.58
0.55
0.67
0.65
0.22
0.72
PBT
3.03
5.79
5.3
6.68
5.1
9.65
8.9
2.08
11.77
0.11
1.74
3.07
0.98
Tax %
0%
0%
14.91%
46.71%
0%
20.31%
0%
201.92%
0%
0%
9.2%
55.05%
0%
Net Profit
3.03
5.79
4.51
3.55
5.1
7.69
8.9
-2.12
11.77
0.11
1.59
1.38
0.98
EPS (₹)
1.44
2.75
2.14
1.69
2.42
3.65
4.23
-1.01
5.59
0.05
0.76
0.66
0.47
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
57
53
63
62
77
85
97
112
93
109
110
106
111
Expenses
54
47
56
58
76
80
90
101
85
100
105
103
112
Operating Profit
3
7
7
4
1
6
8
11
8
9
5
3
-1
OPM %
6%
13%
11%
7%
1.5%
7%
8%
10%
9%
8%
4.4%
3.1%
-1%
Other Income
2
5
3
5
5
0
4
11
9
14
23
16
10
Interest
2
1
2
1
1
0
0
0
0
0
0
0
0
Depreciation
6
1
3
3
3
3
1
2
1
2
2
2
2
PBT
-3
10
6
5
3
3
11
20
16
21
26
17
6
Tax %
-48%
30%
55%
39%
63%
36%
33%
28%
21%
19%
24%
10%
—
Net Profit
-1
7
3
3
1
2
7
14
13
17
20
15
4
EPS (₹)
-0.67
3.26
1.2
1.34
0.48
0.88
3.45
6.7
5.98
7.98
9.27
7.13
1.94
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
21
21
21
21
21
21
21
21
21
21
21
21
Reserves
66
72
74
77
77
79
87
101
114
131
151
165
Borrowings
29
24
11
6
2
0
0
6
2
5
0
3
Other Liabilities
13
27
20
18
21
21
33
28
30
25
51
53
Total Liabilities
128
144
126
122
121
121
140
155
167
182
223
242
Fixed Assets
5
15
15
10
8
6
7
9
7
11
21
20
CWIP
0
0
0
0
0
1
2
0
0
0
0
0
Investments
10
12
13
31
49
57
51
75
78
98
118
142
Other Assets
113
118
97
81
65
58
81
71
82
73
84
80
Total Assets
128
144
126
122
121
121
140
155
167
182
223
242
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-2
-22
17
-13
-1
18
-2
10
9
4
18
9
Investing
37
-8
-2
-11
-15
-11
6
-16
2
-13
-12
-11
Financing
7
-6
-15
9
-5
-1
0
5
-4
3
-5
2
Net Cash Flow
42
-36
0
-15
-20
5
4
0
7
-7
1
1
Free Cash Flow
-3
-32
16
-15
-2
15
-5
8
8
-3
7
6
CFO/EBITDA
-92
-277
283
-263
102
324
15
123
155
85
466
369
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
156
234
168
153
142
105
133
124
184
138
155
141
Inventory Days
76
196
131
138
105
90
102
81
84
73
92
73
Days Payable
91
244
140
134
99
98
152
78
100
63
97
98
Cash Conversion Cycle
141
187
159
157
149
97
83
127
168
149
150
116
Working Capital Days
-5
204
174
208
194
125
140
118
152
135
110
71
ROCE %
0%
10%
8%
6%
3%
5%
7%
9%
12%
15%
16%
9%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Alpa Laboratories insights

64 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs0.07%Promot.57.19%FIIs0.35%Others5.68%Public36.71%As ofSep 2026

Documents

Frequently Asked Questions about Alpa Laboratories

What does Alpa Laboratories Ltd do?
Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals[1]
Where is Alpa Laboratories Ltd (ALPA) listed?
Alpa Laboratories Ltd trades as ALPA on the NSE and under code 532878 on the BSE.
Which sector does Alpa Laboratories Ltd belong to?
Alpa Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Alpa Laboratories Ltd?
Alpa Laboratories Ltd has a market capitalisation of ₹110.36 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Alpa Laboratories Ltd?
Alpa Laboratories Ltd trades at a PE ratio of 27.04 as of 29 Oct 2026, on earnings per share of ₹1.94, against a book value of ₹88.53 per share.
What is the 52-week high and low of Alpa Laboratories Ltd?
Over the last 52 weeks Alpa Laboratories Ltd has traded between ₹46.1 and ₹93.85 as of 29 Oct 2026.
What is the Return on Equity (ROE) of Alpa Laboratories Ltd?
Alpa Laboratories Ltd reported a return on equity of 8.06%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals[1]

Website alpalabs.in
CEO Mr. Mahendra Singh Chawla
Employees 453
Listed 2007-08-06
Face Value ₹ 10
Shares Outstanding 2,10,40,600

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ALPA.md for Alpa Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month